Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 4:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 5,220 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Tablet Clear all
Suspended Phase 2Phase 3 Interventional

Effects of 5HTP and LDOPA on CNS Excitability After SCI

NCT04000919
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
5HTP, L-DOPA, Placebo oral tablet, Carbidopa
Drug
Lead sponsor
Jessica M D'Amico
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Oct 16, 2026, 4:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Tolerability of Pirfenidone in Acute Pancreatitis

NCT05350371
View directory record Official record
Conditions
Pancreatitis, Acute
Interventions
Pirfenidone Oral Tablet, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 85 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Birmingham, Alabama • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 16, 2026, 4:45 PM EDT
Completed Phase 2 Interventional Results available

Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL)

NCT02633956
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Obeticholic Acid, Atorvastatin, Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
22
States / cities
Phoenix, Arizona • La Jolla, California • Rialto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Oct 16, 2026, 4:45 PM EDT
Completed Phase 2 Interventional Results available

Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in Women

NCT01729819
View directory record Official record
Conditions
Overactive Bladder
Interventions
Tolterodine tartrate extended release capsules, Desmopressin orally disintegrating tablets, Placebo orally disintegrating tablets
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
24
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Oct 16, 2026, 4:45 PM EDT
Completed Phase 2 Interventional

A Trial of the Safety and Efficacy of K-604 for the Treatment of Atherosclerosis

NCT00851500
View directory record Official record
Conditions
Atherosclerosis
Interventions
K-604, Placebo
Drug · Other
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
19
States / cities
Chandler, Arizona • Litchfield Park, Arizona • Phoenix, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2011 · Synced Oct 16, 2026, 4:45 PM EDT
Completed Phase 4 Interventional

A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Atorvastatin for at Least 4 Weeks.

NCT00754507
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
colesevelam HCl tablets, and atorvastatin tablets, colesevelam HCl placebo tablets and atorvastatin tablets
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
13
States / cities
Los Angeles, California • Castle Rock, Colorado • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2015 · Synced Oct 16, 2026, 4:45 PM EDT
Completed Phase 3 Interventional

Dose Ranging, Safety and Tolerability of TOPROL-XL® Extended-Release Tablets in Hypertensive Pediatric Subjects

NCT00255528
View directory record Official record
Conditions
Hypertension
Interventions
metoprolol succinate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
6 Years to 16 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
30
States / cities
Little Rock, Arkansas • Bellflower, California • Beverly Hills, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2007 · Synced Oct 16, 2026, 4:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer

NCT01211483
View directory record Official record
Conditions
NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions
U3-1287, Erlotinib, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
14
States / cities
Glendale, Arizona • Scottsdale, Arizona • Anaheim, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2021 · Synced Oct 16, 2026, 4:45 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)

NCT02691494
View directory record Official record
Conditions
Uterine Fibroids, Heavy Menstrual Bleeding
Interventions
Elagolix, Placebo for Estradiol/Norethindrone Acetate, Estradiol/Norethindrone Acetate, Placebo for Elagolix
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 51 Years · Female only
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
103
States / cities
Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 89 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 16, 2026, 4:45 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholangitis

NCT03112681
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
Saroglitazar magnesium 2 mg, Saroglitazar magnesium 4 mg, Placebo Oral Tablet
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
9
States / cities
Pasadena, California • Miami, Florida • Marietta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 16, 2026, 4:45 PM EDT
Completed Early Phase 1 Interventional

Trial Comparing a Multi-Modal Pain Protocol With and Without Opioids Following Total Joint Arthroplasty

NCT03845881
View directory record Official record
Conditions
Total Knee Arthroplasty
Interventions
Oxycodone, Placebo Oral Tablet
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 89 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Oct 16, 2026, 4:45 PM EDT
Terminated Phase 3 Interventional Results available

Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1

NCT01345630
View directory record Official record
Conditions
HIV-1
Interventions
Maraviroc, Emtricitabine/tenofovir, darunavir/ritonavir 800/100 mg, placebo for emtricitabine/tenofovir, placebo for maraviroc
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
84
States / cities
Birmingham, Alabama • Hobson City, Alabama • Hayward, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 16, 2026, 4:45 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks

NCT07752407
View directory record Official record
Conditions
Symptomatic Non-erosive Gastroesophageal Reflux Disease
Interventions
Vonoprazan, Placebo
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Mentor, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 16, 2026, 4:45 PM EDT
Completed Phase 4 Interventional Results available

Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia

NCT00492336
View directory record Official record
Conditions
Schizophrenia
Interventions
rasagiline (Pharmacodynamics), Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
5
States / cities
Baltimore, Maryland • Catonsville, Maryland • Dundalk, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 16, 2026, 4:45 PM EDT
Completed Phase 3 Interventional Results available

Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

NCT02799602
View directory record Official record
Conditions
Metastatic Hormone-sensitive Prostate Cancer
Interventions
BAY1841788 / darolutamide (ODM-201), Standard ADT (androgen deprivation therapy), Docetaxel, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
58
States / cities
Chandler, Arizona • Tucson, Arizona • Beverly Hills, California + 52 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 16, 2026, 4:45 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata

NCT03811912
View directory record Official record
Conditions
Alopecia Areata
Interventions
CTP-543, CTP-543 Matching Placebo
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
10
States / cities
Irvine, California • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2022 · Synced Oct 16, 2026, 4:45 PM EDT
Completed Phase 3 Interventional Results available

A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder

NCT01173601
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY2216684, Placebo, SSRI
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
22
States / cities
Irvine, California • La Habra, California • Redlands, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 16, 2026, 4:45 PM EDT
Completed Phase 3 Interventional

Treatment of Erectile Dysfunction - Long Term Safety and Efficacy

NCT01065012
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Udenafil 50 mg, Udenafil 100 mg, Udenafil 150 mg, Placebo Matching 50 mg Udenafil, Placebo Matching 100 mg Udenafil, Placebo Matching 150 mg Udenafil
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
19 Years and older · Male only
Enrollment
1,027 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
72
States / cities
Birmingham, Alabama • Homewood, Alabama • Huntsville, Alabama + 65 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2015 · Synced Oct 16, 2026, 4:45 PM EDT
Completed Phase 4 Interventional Results available

Pioglitazone and Serum Asymmetric Dimethylarginine (ADMA) in Patients With Diabetes

NCT00770367
View directory record Official record
Conditions
Diabetes
Interventions
Pioglitazone then Placebo, Placebo then Pioglitazone
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
40 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 16, 2026, 4:45 PM EDT
Completed Phase 4 Interventional Results available

Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus

NCT00927394
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Valsartan, Placebo for Aliskiren, Placebo for Valsartan
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1,143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
4
States / cities
Newark, Delaware • Kansas City, Missouri • Camden, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2012 · Synced Oct 16, 2026, 4:45 PM EDT
Recruiting Phase 2 Interventional

Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

NCT07298395
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
ENV-294, Placebo
Drug
Lead sponsor
Enveda Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
32
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Beverly Hills, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 16, 2026, 4:45 PM EDT
Terminated Phase 2Phase 3 Interventional

Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®

NCT01908192
View directory record Official record
Conditions
Schizophrenia
Interventions
NaBen®, Placebo
Drug
Lead sponsor
SyneuRx International (Taiwan) Corp
Industry
Eligibility
12 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
20
States / cities
Dothan, Alabama • Bellflower, California • Long Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Oct 16, 2026, 4:45 PM EDT
Completed Phase 3 Interventional Results available

Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder

NCT01629966
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Placebo, Vilazodone
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
37
States / cities
Birmingham, Alabama • Beverly Hills, California • Glendale, California + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Oct 16, 2026, 4:45 PM EDT
Completed Phase 3 Interventional

A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE)

NCT05113745
View directory record Official record
Conditions
Narcolepsy, Cataplexy, Excessive Daytime Sleepiness
Interventions
AXS-12 (reboxetine), Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
15 Years to 75 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
24
States / cities
Phoenix, Arizona • Boulder, Colorado • Colorado Springs, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 16, 2026, 4:45 PM EDT